# Immune Response to Hepatitis B Vaccine Challenge Dose in Subjects Who Received a Primary Neonatal Hepatitis B Vaccine.

> **NCT00456625** · PHASE4 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 76 (actual)

## Conditions studied

- Hepatitis B

## Interventions

- **BIOLOGICAL:** Engerix™-B

## Key facts

- **NCT ID:** NCT00456625
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-04
- **Primary completion:** 2008-01
- **Final completion:** 2008-01
- **Target enrollment:** 76 (ACTUAL)
- **Last updated:** 2016-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00456625

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00456625, "Immune Response to Hepatitis B Vaccine Challenge Dose in Subjects Who Received a Primary Neonatal Hepatitis B Vaccine.". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT00456625. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*